All News
Filter News
Found 192 articles
-
Taysha Gene Therapies announced that it will focus its efforts on clinical programs targeting Rett Syndrome and giant axonal neuropathy (GAN), resulting in a 35% reduction in its workforce.
-
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
3/31/2022
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today provided a business and strategy update and reported 2021 financial results.
-
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/31/2022
Taysha Gene Therapies, Inc. today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update.
-
Four companies, Pipeline Therapeutics, Prothena, Neuroplast, and Taysha Gene Therapies, announced launches of clinical trials in the CNS space.
-
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
3/29/2022
Taysha Gene Therapies, Inc. today announced the initiation of clinical development of TSHA-102 for the treatment of Rett syndrome under a recently approved Clinical Trial Application (CTA) by Health Canada.
-
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
3/24/2022
Taysha Gene Therapies, Inc. today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday, March 31, 2022, at 8:00 AM Eastern Time.
-
Taysha Gene Therapies to Participate in Upcoming April 2022 Investor Healthcare Conferences
3/23/2022
Taysha Gene Therapies, Inc. announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21st Annual Needham Virtual Healthcare Conference.
-
Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference
3/8/2022
Taysha Gene Therapies, Inc. announced its participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Monday, March 14, 2022, and Tuesday, March 15, 2022.
-
Forge Biologics to Participate in Upcoming Investor Conferences and Presentations in March 2022
3/7/2022
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March.
-
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
2/9/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the 18th Annual WORLD Symposium.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
1/31/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today reported positive clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg, as well as long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy (GAN).
-
Taysha said the data for TSHA-101 is the “first-ever to support the bicistronic vector approach in humans delivering both HEXA and HEXB genes in the endogenous ratio.”
-
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101
1/27/2022
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β -Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis.
-
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event
1/3/2022
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event.
-
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy
12/28/2021
Taysha Gene Therapies, Inc. today announced plans to provide clinical data updates, including its intent to host two virtual investor conference calls and webcasts in January 2022.
-
Taysha Gene Therapies Added to the ICE Biotechnology Index
12/23/2021
Taysha Gene Therapies, Inc. today announced that it has been added to the ICE Biotechnology Index (NYSE:ICEBIO) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021.
-
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
12/22/2021
Taysha Gene Therapies, Inc. today announced preliminary clinical safety data for the first-generation construct in CLN7 disease.
-
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease
12/16/2021
Taysha Gene Therapies, Inc. (Nasdaq: TSHA),, today announced the initiation of clinical development of TSHA-118 for the treatment of CLN1 disease under a recently approved Clinical Trial Application (CTA).